Q-omics provides the consensus-scored MS4A2 profile across patient tissues and cancer cell-line models. MS4A2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MS4A2 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, MS4A2 RNA expression shows 22,865 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, BLCA, and BRCA as cancer lineages where MS4A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A2 survival associations across molecular data types. MS4A2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A2 RNA expression–survival associations across cancer types. High MS4A2 expression shows unfavorable associations in UVM, but favorable associations in HNSC, LUAD, KIRC, ACC and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MS4A2 RNA expression.
This table summarizes MS4A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MS4A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A2 shows lower tumor expression in BLCA, COAD, LUAD, LUSC and UCEC and higher tumor expression in KIRC. The BLCA box plot shows higher MS4A2 RNA expression in normal versus tumor tissue (log2 FC = −2.347, t-test p < 0.001).
This table shows molecular features associated with MS4A2 in patient tissues and cancer cell lines. In patient samples, MS4A2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
